Can branded GLP-1 medicines replace compounded weight-loss drugs in Hims & Hers growth strategy?
Lilly is bringing Zepbound and Foundayo to Hims & Hers, turning a former GLP-1 disruptor into a branded obesity-drug distribution channel.
Features & Analysis
Pharma & Biotech
Eli Lilly brings Zepbound and Foundayo to Hims & Hers, but who gains most from the deal?
Eli Lilly and Hims & Hers expand access to Zepbound and Foundayo from $149 monthly. Discover the impact on obesity medicine distribution.
Pharma & Biotech
GLP-1 prescribing rises 310-fold among U.S. children aged 8–11 with obesity
An NYU Langone study of more than 3.5 million children found rapidly increasing off-label GLP-1 prescribing below age 12, concentrated among children with severe obesity and related disease.
Pharma & Biotech
Can low doses of Ozempic, Wegovy, Mounjaro and Zepbound still cause weight loss?
A new real-world study of sustained low-dose semaglutide and tirzepatide found measurable weight loss without escalation to standard maintenance doses, but researchers stress that prescription records do not prove intentional GLP-1 microdosing and the observational findings cannot establish cause and effect.
Pharma & Biotech
Neurocrine NBIP-1968 enters Phase 1 as triple-agonist obesity race accelerates
Neurocrine Biosciences has initiated a first-in-human Phase 1 study of NBIP-1968, a once-weekly experimental obesity treatment designed to activate the GLP-1, GIP and glucagon receptors through a single molecule. The August 7, 2026 development marks Neurocrine Biosciences’ entry into clinical testing with an incretin-based obesity candidate. The study will initially examine single ascending doses in
Pharma & Biotech
Novellia’s GLP-1 registry found a surprising weight-loss pattern, but what does it really prove?
See how Novellia’s GLP-1 registry could sharpen real-world evidence while facing tests on validation, bias, privacy and payer use.
Pharma & Biotech
Evidation GLP-1 study reveals major growth runway but exposes widening access gaps
Discover how Evidation’s 165,000-person study reveals GLP-1 growth potential, access gaps and persistence risks shaping obesity care. Read more.
Pharma & Biotech
Apotex Sevmia challenges Wegovy as generic GLP-1 competition begins in Canada
Read how Apotex’s Sevmia approval could reshape Canada’s semaglutide market, and why dosing, pricing and reimbursement still matter.
Pharma & Biotech
insitro’s MASH candidate adds a fibrosis signal, but human proof remains the real test
AI met MASH fibrosis, but mouse data are only the first test. See why insitro’s CTRO-1013 signal matters now.
Pharma & Biotech
Pfizer’s Phase 2b obesity data put monthly GLP-1 dosing back in investor focus
Find out how Pfizer’s berobenatide Phase 2b data could reshape monthly GLP-1 obesity treatment and late-stage trial strategy.